Description

Product Description

Introduction

Lefleuganan (CAS 2233558-98-8) is an advanced antiprotozoal agent developed for scientific and laboratory research. Protozoal infections remain one of the most significant health challenges worldwide, affecting millions annually through diseases such as malaria, leishmaniasis, and trypanosomiasis. Lefleuganan represents a valuable research molecule designed to help investigators explore mechanisms of protozoal survival, pathogenesis, and potential treatment pathways.

Unlike broad-spectrum antibiotics, Lefleuganan shows targeted antiprotozoal activity, which makes it useful for precision-based studies. As emerging drug resistance continues to complicate protozoal disease management, compounds like Lefleuganan provide researchers with a much-needed tool to investigate resistance mechanisms and novel treatment strategies.

Research Significance

Protozoal diseases impose a dual burden: they are not only medically challenging but also socially and economically disruptive. Malaria alone accounts for hundreds of thousands of deaths each year, particularly in endemic regions. Drug resistance to current therapies, such as chloroquine or artemisinin, highlights the urgent need for new molecular scaffolds. Lefleuganan provides such a scaffold for mechanistic exploration and therapeutic development.

Key Attributes

• Potent antiprotozoal activity against multiple protozoal species.

• High purity (?98%), verified by HPLC.

• Manufactured under GMP compliance, ensuring batch consistency.

• Applicable in vitro and in vivo research, including protozoal infection models.

• Versatile solubility, allowing use across multiple experimental setups.

In summary, Lefleuganan offers researchers a powerful and reliable compound to push forward protozoal research in drug resistance, pharmacodynamics, and comparative biology.

Product Specifications

Extended Notes

The high-purity, GMP-compliant nature of Lefleuganan ensures reproducible results across multiple experimental setups. Its solubility profile makes it adaptable for both cell culture models and animal model investigations, supporting studies ranging from basic protozoal biology to translational drug development.

Mechanism of Action & Research Applications

Mechanism of Action

Lefleuganan is believed to act through selective disruption of protozoal metabolic pathways, interfering with parasite replication and survival. Potential targets under study include:

• Nucleic acid synthesis inhibition, impairing protozoal genetic replication.

• Mitochondrial pathway interference, reducing parasite energy metabolism.

• Protein synthesis disruption, limiting essential enzymatic function.

• Membrane integrity compromise, leading to protozoal lysis.

By disrupting these survival mechanisms, Lefleuganan helps researchers better understand protozoal vulnerabilities and pathways that could serve as drug targets.

Research Applications

1. Protozoal Pathogenesis Studies
   Lefleuganan aids in identifying critical survival pathways used by protozoa.

2. Drug Resistance Research
   Comparative studies with resistant and sensitive protozoal strains help determine how resistance emerges.

3. Combination Therapy Models
   Researchers can test Lefleuganan alongside antimalarials or antileishmanial agents for synergistic effects.

4. Animal Infection Models
   Useful in murine or primate parasitemia studies, supporting translational research.

5. Comparative Pharmacology
   Enables mapping of how Lefleuganan performs relative to other antiprotozoal candidates.

   

Side Effects (For Reference in Research Models)

While Lefleuganan is not intended for therapeutic use, preclinical research models have documented possible side effects:

• Hepatotoxicity: Elevated liver enzymes in some models.

• Renal markers: Dose-dependent effects in long-term administration.

• Gastrointestinal disturbances: Observed at higher concentrations.

• Cytotoxicity at supratherapeutic doses: Noted in some in vitro studies.

• Resistance potential: Long exposure may select resistant protozoal strains.

Researchers should carefully design protocols to optimize dosing and minimize confounding variables such as solvent effects.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

•  CAS 2233558-98-8

•  GMP supplier

•  antiprotozoal compound

•  bulk powder

• Antiprotozoal drug discovery compound

• High purity Lefleuganan for research